## **Special Issue**

# Pathophysiology, Diagnosis and Therapy of Sepsis

#### Message from the Guest Editors

Sepsis is a clinical syndrome that results from the dysregulated inflammatory response to infection that leads to organ dysfunction. The resulting losses to society in terms of financial burden, morbidity, and mortality are enormous. Comprehensively defining "sepsis" has been the subject of constant development and refinement over the last decades. Although our understanding of sepsis origin, pathophysiology, and immunological mechanisms have progressed over the last three decades, our options for specific and successful therapeutic interventions remain limited. Only timely fluid resuscitation and early administration of broad-spectrum antibiotics have been shown to reduce mortality. A decisive factor is the time of correct diagnosis and the initiation of causal, supportive, and adjunctive measures. Moreover, the high heterogeneity of host response to infections and its changes with time require a personalized approach to patient management. This Special Issue focuses on manuscripts related to the recent advancements in the knowledge of sepsis mechanisms, diagnostic protocols including new biomarkers, and new developing therapies for improving the prognosis of septic patients.

#### **Guest Editors**

Dr. Massimo Girardis

Dr. Marc Leone

Dr. Anne-Claire Lukaszewicz

Dr. Gennaro De Pascale

#### Deadline for manuscript submissions

closed (30 November 2023)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/149214

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



### **About the Journal**

#### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

#### Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

#### **Author Benefits**

#### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

